Can-Fite Biopharma Ltd ADR (CANF) Stock Price, Quote & News

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 924 1114

Fax: 972 3 924 9378

Website: www.canfite.com

Address:

26 Ben Gurion Street, Ramat Gan, Israel

GeeJoon Apr. 2 at 12:37 AM

$CANF easter egg... psoriasis p3 interim result meet all end points, piclidenosen may be the best drug for patients who are suffering from both psoriasis and liver disease, bp would thrn offer new deals worth billion to canf, hope so

1 · Reply

GeeJoon Apr. 1 at 12:32 AM

$CANF Q2 starts...which one will be released first? success rate of NDA is above 80% upon good p3 interim result...200m market cap at least? - pancreatic cancer p2a result - psoriasis p3 interim result

0 · Reply

StreetwiseReports Mar. 30 at 9:59 PM

Biotech Company Uncovers Breakthrough Canine Arthritis Treatment https://ow.ly/FQIJ50YAXl0 Israeli co. Can-Fite BioPharma Ltd. ( $CANF ) teamed up with Vetbiolix to trial Piclidenoson for dogs, with Phase 2 results due Q3 2026. Yet, one analyst still rates the stock as a Hold. Read on to see why.

0 · Reply

GeeJoon Mar. 30 at 12:45 PM

$CANF 2026...all these catalysts are money...100x - Qx: pancreatic cancer p2a result - Q2: psoriasis p3 interim result - Q3: MASH p2b result - Q3: dogs osteoarthritis p2 result - Q4: liver cancer HCC CPB7 p3 interim result

0 · Reply

DARKP00L Mar. 30 at 11:30 AM

$CANF 07:25 on Mar. 30 2026 Can-Fite Biopharma's Veterinary Partner Vetbiolix Completes Enrollment In Phase 2 Study Of Piclidenoson For Osteoarthritis In Dogs; Topline Data Are Expected In Q3 2026 #tradeideas

1 · Reply

GeeJoon Mar. 29 at 9:06 AM

$CANF Dr. Pnina Fishman will turn 78 old in August, which will be her best birthday gift? - pancreatic cancer p2a result - MASH p2b result - psoriasis p3 interim result - liver cancer HCC CPB7 p3 interim result - new partnership deal

0 · Reply

OfficialStocktwitsUser Mar. 28 at 1:00 AM

$CANF RSI: 21.69, MACD: -0.3567 Vol: 0.78, MA20: 3.88, MA50: 4.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

GeeJoon Mar. 27 at 12:02 PM

$CANF 2026... - pancreatic cancer p2a result - MASH p2b result - psoriasis p3 interim result - liver cancer HCC CPB7 p3 interim result

1 · Reply

Peaceouty Mar. 25 at 10:51 PM

$CANF seems like active dilution still… insane ..

1 · Reply

GeeJoon Mar. 25 at 12:07 AM

$CANF 6.5m cap, 10m cash, 2 pivotal p3, NDA soonest in 2027, 40% shares @$5 hold by unknown

0 · Reply

Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs

Mon, 30 Mar 2026 07:20:00 -0400 - 3 days ago

Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Thu, 26 Mar 2026 09:27:00 -0400 - 7 days ago

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

2026-03-17T13:28:03.000Z - 16 days ago

Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment

Tue, 17 Mar 2026 07:47:00 -0400 - 16 days ago

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

2026-03-04T16:50:16.000Z - 4 weeks ago

Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants

Wed, 04 Mar 2026 10:07:28 -0500 - 4 weeks ago

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

2026-03-04T12:34:33.000Z - 4 weeks ago

Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study

Wed, 04 Mar 2026 07:00:00 -0500 - 4 weeks ago

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

2026-02-17T12:36:34.000Z - 6 weeks ago

Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results

2026-02-09T12:30:05.000Z - 7 weeks ago

Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson

2026-02-05T12:33:49.000Z - 2 months ago

Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant

2026-01-20T12:37:35.000Z - 2 months ago

Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial

2025-12-23T22:55:20.000Z - 3 months ago

Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split

2025-12-23T22:25:23.000Z - 3 months ago

Can-Fite BioPharma (CANF) Announces Significant Reverse Split

Tue, 23 Dec 2025 16:46:00 -0500 - 3 months ago

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

2025-12-17T13:30:15.000Z - 3 months ago

CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News

2025-12-16T15:29:50.000Z - 3 months ago

CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position

Tue, 16 Dec 2025 09:19:00 -0500 - 3 months ago

Can-Fite Provides Update on Clinical and Financial Status

2025-11-24T12:30:24.000Z - 4 months ago

Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025

2025-11-20T12:42:31.000Z - 4 months ago

Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment

Thu, 20 Nov 2025 07:00:00 -0500 - 4 months ago

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

2025-11-18T20:00:37.000Z - 4 months ago

CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News

2025-11-18T12:30:20.000Z - 4 months ago

Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival

2025-11-04T12:01:46.000Z - 5 months ago

CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News

2025-09-16T12:32:06.000Z - 7 months ago

CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News

2025-09-15T12:40:09.000Z - 7 months ago

Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment

Thu, 28 Aug 2025 08:47:00 -0400 - 7 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Wed, 30 Jul 2025 07:04:00 -0400 - 8 months ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Mon, 28 Jul 2025 12:24:00 -0400 - 8 months ago

Can-Fite Announces Up To $15.0 Million Public Offering

Mon, 28 Jul 2025 07:00:00 -0400 - 8 months ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Thu, 17 Apr 2025 08:55:00 -0400 - 1 year ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Mon, 14 Apr 2025 14:28:00 -0400 - 1 year ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Thu, 20 Mar 2025 09:45:00 -0400 - 1 year ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Wed, 19 Mar 2025 09:00:00 -0400 - 1 year ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Mon, 03 Mar 2025 06:00:00 -0500 - 1 year ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Mon, 10 Feb 2025 07:10:00 -0500 - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Wed, 05 Feb 2025 07:00:00 -0500 - 1 year ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Mon, 30 Dec 2024 07:00:00 -0500 - 1 year ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Fri, 22 Nov 2024 09:00:00 -0500 - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mon, 11 Nov 2024 07:00:00 -0500 - 1 year ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Mon, 04 Nov 2024 07:08:00 -0500 - 1 year ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Fri, 18 Oct 2024 09:06:00 -0400 - 1 year ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Wed, 09 Oct 2024 07:00:00 -0400 - 1 year ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Mon, 16 Sep 2024 07:00:00 -0400 - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Thu, 29 Aug 2024 08:15:00 -0400 - 1 year ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Aug 9, 2024, 9:00 AM EDT - 1 year ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Aug 8, 2024, 7:01 PM EDT - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Provides Namodenoson Patent Update

Jul 17, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

May 29, 2024, 7:00 AM EDT - 2 years ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 27, 2024, 7:00 AM EDT - 2 years ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 23, 2024, 7:00 AM EDT - 2 years ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 13, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 10, 2024, 9:00 AM EDT - 2 years ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

May 9, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 6, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Reports 2023 Financial Results and Clinical Update

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Feb 28, 2024, 7:00 AM EST - 2 years ago

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

GeeJoon Apr. 2 at 12:37 AM

1 · Reply

GeeJoon Apr. 1 at 12:32 AM

0 · Reply

StreetwiseReports Mar. 30 at 9:59 PM

0 · Reply

GeeJoon Mar. 30 at 12:45 PM

0 · Reply

DARKP00L Mar. 30 at 11:30 AM

1 · Reply

GeeJoon Mar. 29 at 9:06 AM

0 · Reply

OfficialStocktwitsUser Mar. 28 at 1:00 AM

0 · Reply

GeeJoon Mar. 27 at 12:02 PM

$CANF 2026... - pancreatic cancer p2a result - MASH p2b result - psoriasis p3 interim result - liver cancer HCC CPB7 p3 interim result

1 · Reply

Peaceouty Mar. 25 at 10:51 PM

$CANF seems like active dilution still… insane ..

1 · Reply

GeeJoon Mar. 25 at 12:07 AM

$CANF 6.5m cap, 10m cash, 2 pivotal p3, NDA soonest in 2027, 40% shares @$5 hold by unknown

0 · Reply

Farhas80 Mar. 24 at 6:34 PM

$CANF How far this stock will go down before any rebound. Management sucks.

0 · Reply

Peaceouty Mar. 20 at 10:33 PM

$CANF These people are running a snake oil scam for over 20 years. Unbelievable!

0 · Reply

GeeJoon Mar. 20 at 4:36 PM

$CANF the valuation is insane, 7m only with 2 pivotal P3, tutes are scared of CANF management and shitty price action

1 · Reply

GeeJoon Mar. 20 at 4:31 PM

$CANF veterinary market looks more promising...upfront and royalties on sales upon regulatory approval for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch.

0 · Reply

Farhas80 Mar. 20 at 1:57 PM

$CANF This stupid stock keep going down because of stupid management. I thought I bought good price around 4:50. No news no rebound.

0 · Reply

PhishTourFunds Mar. 20 at 12:34 PM

$CANF 200SMA is about $10.50 now Massive volume and price pump to $12 earlier this month looks like an exit event similar to mid November ‘25.

0 · Reply

GeeJoon Mar. 18 at 4:16 PM

$CANF will they attend Bio Europe and disclose the data of pancreatic cancer p2a

2 · Reply

Farhas80 Mar. 18 at 3:14 PM

$CANF just bought 5k for rebound.

0 · Reply

Farhas80 Mar. 18 at 3:02 PM

$CANF Stock is 10 years low and management is quite.

0 · Reply

Farhas80 Mar. 17 at 7:46 PM

$CANF we touching almost 10 years low and company still not releasing something good.

0 · Reply

GeeJoon Mar. 17 at 2:19 PM

$CANF u know why no tutes investing this shit, all CANF claimed were only patent, safety, patent, safety

0 · Reply

DARKP00L Mar. 17 at 11:50 AM

$CANF 07:49 on Mar. 17 2026 Can‑Fite BioPharma Secures Israeli Patent Allowance For A3AR Agonists, Covering Namodenoson In Obesity And Fat‑Loss Use #tradeideas

0 · Reply

Market Cap	2.02M
Revenue (ttm)	410,000.00
Net Income (ttm)	-9.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,397.56%
Debt to Equity Ratio	0.00

Volume	23,900
Avg Vol	849,964
Day's Range	N/A - N/A
Shares Out	655,000.00
Stochastic %K	27%
Beta	1.06
Analysts	Sell
Price Target	$70.00